Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-07Clinical Trial Update: A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating a triplet regimen of epcoritamab with lenalidomide and tafasitamab in Diffuse Large B-Cell Lymphoma has been with…
-
CLINICAL_TRIALS withdrawal · 2026-01-30Clinical Trial Update: Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating Rituximab, Venetoclax, and Bortezomib for relapsed or refractory diffuse large B-cell lymphoma has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2025-09-17Clinical Trial Update: A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating glofitamab for minimal residual disease in patients with diffuse large B-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]
The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has be…
-
CLINICAL_TRIALS withdrawal · 2025-05-06Clinical Trial Update: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL [Phase 1]
Phase 1 trial evaluating PD-1, LAG-3, and TIM-3 checkpoint blockade for diffuse large B-cell lymphoma has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-02-21Clinical Trial Update: QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma [Phase 1]
A Phase 1 trial of CD19 t-haNK for diffuse large B-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma [Phase 1]
A Phase 1 clinical study evaluating duvortuxizumab plus ibrutinib in lymphomas has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-11-12Clinical Trial Update: Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah [Phase 1]
A Phase 1 trial investigating lymphodepletion strategies to improve outcomes in patients with diffuse large B-cell lymphoma treated with Kym…
-
CLINICAL_TRIALS withdrawal · 2024-05-21Clinical Trial Update: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma [Phase 2]
A Phase 2 trial comparing R-DHAP versus POLA-R-DHAP followed by autologous transplant for relapsed or refractory diffuse large B-cell lympho…
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]
A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has bee…
-
CLINICAL_TRIALS withdrawal · 2018-04-09Clinical Trial Update: Durvalumab in DLBCL After Autologous Transplant [Phase 2]
A Phase 2 trial evaluating durvalumab for diffuse large B-cell lymphoma after autologous transplant has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-12-07Clinical Trial Update: Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma [Phase 1, Phase 2]
Clinical trial update shows the early-phase study of ABC294640 (opaganib) in refractory/relapsed diffuse large B-cell lymphoma and Kaposi sa…
-
CLINICAL_TRIALS withdrawal · 2017-05-23Clinical Trial Update: Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma [Phase 1]
A Phase 1 safety and efficacy trial of CNOP chemotherapy for diffuse large B-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-19Clinical Trial Update: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]
The Phase 2 trial of Brentuximab Vedotin, Bendamustine, and Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdr…
-
CLINICAL_TRIALS withdrawal · 2016-11-25Clinical Trial Update: Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
This clinical trial update states that the Phase 2 study of MDV9300 in relapsed or refractory diffuse large B-cell lymphoma has been withdra…
-
CLINICAL_TRIALS withdrawal · 2016-11-02Clinical Trial Update: A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) [Phase 2]
The NAVIGATE Phase 2 study evaluating navitoclax added to bendamustine and rituximab for relapsed diffuse large B-cell lymphoma has been wit…
-
CLINICAL_TRIALS withdrawal · 2016-10-14Clinical Trial Update: R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma [Phase 2]
A phase 2 trial of R-CHOP-B (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Bevacizumab) for diffuse large B-cell ly…
-
CLINICAL_TRIALS withdrawal · 2016-09-15Clinical Trial Update: AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1]
Phase 1 trial of AZD2014 plus novel anti-cancer agents for relapsed or refractory diffuse large B-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-08-11Clinical Trial Update: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/Phase 2 study of Rituximab, Romidepsin, and Lenalidomide for recurrent or refractory B-cell non-Hodgkin lymphoma has been withdraw…
-
CLINICAL_TRIALS withdrawal · 2016-03-16Clinical Trial Update: Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating RICE followed by GARD for relapsed or refractory diffuse large B-cell lymphoma was withdrawn, with no re…
-
CLINICAL_TRIALS withdrawal · 2016-03-03Clinical Trial Update: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating rituximab in combination with chemotherapy for untreated high- or high-intermediate-risk diffuse large B-cell lym…
-
CLINICAL_TRIALS withdrawal · 2016-02-23Clinical Trial Update: R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL [Phase 3]
Phase 3 trial comparing R-CHOP alone versus R-CHOP with radiotherapy for localized CD20+ Diffuse Large B-Cell Lymphoma was withdrawn (sponso…
-
CLINICAL_TRIALS withdrawal · 2016-01-06Clinical Trial Update: A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 1]
The trial, a Phase Ib study of belinostat with RDHAP chemotherapy for relapsed or refractory diffuse large B-cell lymphoma, has been withdra…
-
CLINICAL_TRIALS withdrawal · 2015-05-06Clinical Trial Update: The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
The trial evaluating whether interim PET/CT after two cycles of chemotherapy can predict progression in non-Hodgkin lymphoma has been withdr…
-
CLINICAL_TRIALS withdrawal · 2015-04-17Clinical Trial Update: A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen [Phase 3]
A Phase 3 trial comparing two radioimmunotherapy regimens (I-131 tositumomab vs ibritumomab tiuxetan) for follicular and other non-Hodgkin l…